Back to Results

SGNTUC-016: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic Her2+ breast cancer

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Scope

National

Locations

Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital

Principal Investigator
Diana Medgyesy,  MD

Diana Medgyesy, MD

Study ID

Protocol Number: 19-6076

More information available at ClinicalTrials.gov: NCT03975647

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers